News

Published on 8 Mar 2024 on Zacks via Yahoo Finance

What Makes Replimune Group, Inc. (REPL) a New Buy Stock


Article preview image

Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

NASDAQ.REPL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Tesla, Nvidia among Friday's market cap stock movers By Investing.com

Tesla, Nvidia among Friday's market cap stock movers

Investing.com 22 Nov 2024

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead...

Zacks · via Yahoo Finance 22 Nov 2024

Replimune's stock surges 19% after-hours on FDA BLA submission By Investing.com

Shares of Replimune Group Inc (NASDAQ:REPL) surged more than 19% in after-hours trading following...

Investing.com 22 Nov 2024

Replimune group's chief medical officer sells shares worth $78,111 By...

The shares were sold at a price of $10.78 each, amounting to a total transaction value of $78,111...

Investing.com 20 Nov 2024

Replimune's chief commercial officer sells $56,131 in stock By Investing.com

According to a filing with the Securities and Exchange Commission, Sarchi sold 5,207 shares at a...

Investing.com 20 Nov 2024

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings

Overview of the Recent Transaction On September 30, 2024, Morgan Stanley executed a significant t...

GuruFocus.com · via Yahoo Finance 8 Oct 2024

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

Shares of Replimune Group, Inc. (REPL) have gained 16.4% over the past four weeks to close the la...

Zacks via Yahoo Finance 11 Mar 2024

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a ...

Zacks via Yahoo Finance 8 Mar 2024

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move...

Shares of Replimune Group, Inc. (REPL) have gained 0.8% over the past four weeks to close the las...

Zacks via Yahoo Finance 23 Feb 2024

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway

<img src=https://s.yimg.com/ny/api/res/1.2/GFFacjMQE5JFxUpwjOKI8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyM...

GuruFocus.com via Yahoo Finance 8 Feb 2024